Allergan migraine portfolio grows with Merck CGRP antagonists
This article was originally published in Scrip
Executive Summary
Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.